Download PDF
Osteologie 2014; 23(01): 56-60
DOI: 10.1055/s-0037-1620028
Der interessante Fall
Schattauer GmbH

Systemische Mastozytose – eine seltene Ursache einer fortgeschrittenen Osteoporose beim Mann

F. Jockers
1   Klinik für Endokrinologie, Diabetologie und Metabolismus, Universitätsspital Basel, Schweiz
,
M. E. Kraenzlin
1   Klinik für Endokrinologie, Diabetologie und Metabolismus, Universitätsspital Basel, Schweiz
2   Endokrinologische Praxis & Labor, Basel, Schweiz
,
C. Kraenzlin
2   Endokrinologische Praxis & Labor, Basel, Schweiz
,
C. Meier
1   Klinik für Endokrinologie, Diabetologie und Metabolismus, Universitätsspital Basel, Schweiz
2   Endokrinologische Praxis & Labor, Basel, Schweiz
› Author Affiliations
Further Information

Publication History

eingereicht: 13 September 2013

angenommen: 17 September 2013

Publication Date:
11 January 2018 (online)

    Permissions and Reprints

 

 

  • Literatur

  • 1 Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis: a disease of the hematopoietic stem cell. Deutsches Arzteblatt international 2008; 105 (40) 686-692.
    PubMedGoogle Scholar
  • 2 Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112 (04) 946-956.
    CrossrefPubMedGoogle Scholar
  • 3 Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. The Journal of molecular diagnostics: JMD 2011; 13 (02) 180-188.
    CrossrefPubMedGoogle Scholar
  • 4 Maier GS, Percic D, Maus U, Kurth AA. Mastocytosis-induced osteoporosis. Osteologie 2013; 22 (02) 135-139.
    Google Scholar
  • 5 Kirshenbaum AS, Kettelhut BV, Metcalfe DD, Garriga MM. Mastocytosis in infants and children: recognition of patterns of skin disease. Allergy proceedings: the official journal of regional and state allergy societies 1989; 10 (01) 17-21.
    CrossrefPubMedGoogle Scholar
  • 6 Amon U, Hartmann K, Horny HP, Nowak A. Mastocytosis – an update. Journal der Deutschen Dermatologischen Gesellschaft. 2010 08. 09 695-711 quiz 712.
    Google Scholar
  • 7 Soter NA. Mastocytosis and the skin. Hematology/ oncology clinics of North America. 2000 14. (03) 537-555 vi..
    PubMedGoogle Scholar
  • 8 Bains SN, Hsieh FH. Current approaches to the diagnosis and treatment of systemic mastocytosis. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 2010 104. (01) 1-10 quiz 12, 41..
    PubMedGoogle Scholar
  • 9 Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. The Journal of molecular diagnostics. 2006 08. (04) 412-419 PubMed PMID: 16931579..
    Google Scholar
  • 10 Castells M, Austen KF. Mastocytosis: mediatorrelated signs and symptoms. International archives of allergy and immunology 2002; 127 (02) 147-152.
    CrossrefPubMedGoogle Scholar
  • 11 Sperr WR, Jordan JH, Fiegl M. et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. International archives of allergy and immunology 2002; 128 (02) 136-141.
    CrossrefPubMedGoogle Scholar
  • 12 Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunology and allergy clinics of North America 2006; 26 (03) 451-463.
    CrossrefPubMedGoogle Scholar
  • 13 Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology: journal of immunopathology, molecular and cellular biology 2007; 74 (02) 121-132.
    CrossrefPubMedGoogle Scholar
  • 14 Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25 (07) 543-551.
    CrossrefPubMedGoogle Scholar
  • 15 Valent P, Akin C, Sperr WR. et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122 (05) 695-717.
    CrossrefPubMedGoogle Scholar
  • 16 Kraenzlin ME, Seibel MJ, Meier C. Diagnostik und Therapie der Osteoporose. Teil 1: Diagnostik und Frakturrisikoevaluation. Schweiz Med Forum 2006; 06: 712-717.
    Google Scholar
  • 17 Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Drugs Aging 1998; 13 (06) 421-434.
    CrossrefPubMedGoogle Scholar
  • 18 Delling G, Ritzel H, Werner M. Histologische Charakteristika und Haufigkeit der sekundaren Osteoporose bei systemischer Mastozytose. Eine retrospektive Analyse an 158 Fallen. Der Pathologe 2001; 22 (02) 132-140.
    CrossrefPubMedGoogle Scholar
  • 19 Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008; 358 (14) 1474-1482.
    CrossrefPubMedGoogle Scholar
  • 20 Barete S, Assous N, de Gennes C. et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69 (10) 1838-1841.
    CrossrefPubMedGoogle Scholar
  • 21 Rossini M, Zanotti R, Bonadonna P. et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011; 49 (04) 880-885.
    CrossrefPubMedGoogle Scholar
  • 22 van der Veer E, van der Goot W, de Monchy JG. et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012; 67 (03) 431-438.
    CrossrefPubMedGoogle Scholar
  • 23 Seitz S, Barvencik F, Koehne T. et al. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 2013; 24 (08) 2325-2334.
    CrossrefPubMedGoogle Scholar
  • 24 Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006; 36 (01) 32-36.
    CrossrefPubMedGoogle Scholar
  • 25 Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. International archives of allergy and immunology 2002; 128 (04) 344-350.
    CrossrefPubMedGoogle Scholar
  • 26 Guillaume N, Desoutter J, Chandesris O. et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013; 126 (01) 75-77. e1
    Google Scholar
  • 27 Chen W, Beck I, Schober W. et al. Human mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp Dermatol 2010; 19 (03) 302-304.
    CrossrefPubMedGoogle Scholar
  • 28 Cummings SR, San JMartin, McClung MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361 (08) 756-765.
    CrossrefPubMedGoogle Scholar